Biologic Therapy and Severe Asthma in Children

Daniele Russo1,2, Paola Di Filippo1,2, Marina Attanasi1,2

  • 1Department of Pediatrics, University of Chieti, 66100 Chieti, Italy.

Biomedicines
|July 2, 2021
PubMed

Insights

New biologic therapies offer targeted treatment for severe asthma in children. These innovative treatments focus on specific inflammatory pathways, improving care for young patients with complex respiratory conditions.

Area of Science:

  • Pediatric Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Severe asthma is a complex, chronic respiratory condition affecting many children.
  • Distinct asthma endotypes in children involve specific molecular pathways.
  • Biologic therapies have emerged as a significant advancement in managing chronic allergic diseases.

Purpose of the Study:

  • To review the latest evidence on biologic therapies for severe asthma in pediatric and adolescent populations.
  • To detail the use, indications, efficacy, and safety of these innovative treatments.
  • To highlight the impact of biologics on managing severe pediatric asthma.

Main Methods:

  • Systematic review of recent scientific literature.
  • Analysis of clinical trial data and real-world evidence.
  • Focus on studies involving children and adolescents with severe asthma.

Main Results:

  • Biologic therapies demonstrate significant efficacy in managing severe pediatric asthma.
  • Targeting specific type 2 inflammatory mediators is key to treatment success.
  • These therapies have revolutionized the care approach for young asthma patients.

Conclusions:

  • Biologics represent a major therapeutic advance for severe asthma in children and adolescents.
  • Evidence supports their use for specific asthma endotypes.
  • Further research will continue to refine their application and safety profile.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.2K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
886
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
970
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.4K